Dolo

Researchers are conducting a multicenter prospective observational study focused on patients with newly diagnosed oligometastatic prostate cancer, defined by specific criteria that exclude high metastatic volume disease. The study aims to create a registry of patients from major urological centers in the Triveneto region to assess the cancer outcomes and quality of life impacts of local treatments on the primary tumor alongside systemic hormonal therapies. Participants receive local treatment for the primary prostate tumor, which may include surgery or radiotherapy, combined with systemic hormone therapy. The systemic treatment options include androgen deprivation therapy alone or combined with Docetaxel or androgen receptor signaling inhibitors. Patients must have low-volume metastatic disease according to CHAARTED criteria, without prior local treatment of the primary tumor, and may have been on systemic therapy for less than six months before enrollment. During the study, researchers will monitor overall survival from the start of the chosen treatment up to three years. Participants will be evaluated for cancer progression, quality of life, and treatment effects while receiving local and systemic therapies. The study involves informed consent, regular follow-ups, and assessment of performance status to ensure safety and effectiveness of the combined treatment approach over time.